Peter Kiener

Director/Board Member chez LAVA THERAPEUTICS N.V. Fortune : 675 $ au 31/03/2024

Profil

Peter Alec Kiener founded Zyngenia, Inc. in 2009, where he worked as President, Chief Executive Officer & Director from 2009 to 2013.
Dr. Kiener also currently works at Resolve Therapeutics LLC, as Chairman, AbCellera Boston, Inc., as Director, Pieris Pharmaceuticals, Inc., as Independent Director from 2018, Cue Biopharma, Inc., as Independent Director from 2020, LAVA Therapeutics NV, as Non-Executive Director from 2023, Wugen, Inc., as Director, Itolerance, Inc., as Director, Intermediate Capital Group Plc (Private Equity), as Venture Partner, and Bridge Valley Ventures LLP, as Venture Partner.
Dr. Kiener also formerly worked at Cereius, Inc., as Chief Executive Officer from 2019 to 2020, GT Biopharma, Inc., as Director from 2018 to 2019, Receptor BioLogix, Inc., as Director, Adheron Therapeutics, Inc., as Director, Virdante Pharmaceuticals, Inc., as Director, Viral Logic Systems Technology Corp., as Director, Bristol Myers Squibb Co., as Head-Global Research & Development from 1983 to 2001, MedImmune LLC, as Executive Vice President-Research & Development from 2001 to 2009, AstraZeneca PLC, as Executive Vice President in 2009, the University of Oxford, as Principal, the University of North Texas, as Assistant Professor from 1982 to 1983, the University of Massachusetts, as Research Associate from 1978 to 1982, Ambrx, Inc., as Chief Science Officer from 2013 to 2014, and Sucampo Pharmaceuticals LLC, as Chief Scientific Officer from 2014 to 2018.
Dr. Kiener received his doctorate degree in 1978 from the University of Oxford and undergraduate degree in 1973 from the University of Lancaster.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
CUE BIOPHARMA, INC. 0,00%	02/01/2024	357 ( 0,00% )	675 $	31/03/2024
PIERIS PHARMACEUTICALS, INC. -.--%	21/06/2023	0 ( -.--% )	- $	31/03/2024

Postes actifs de Peter Kiener

Sociétés	Poste	Début
CUE BIOPHARMA, INC.	Director/Board Member	01/04/2020
PIERIS PHARMACEUTICALS, INC.	Director/Board Member	10/09/2018
LAVA THERAPEUTICS N.V.	Director/Board Member	01/01/2023
Wugen, Inc.	Director/Board Member	-
Itolerance, Inc.	Director/Board Member	-
Bridge Valley Ventures LLP	Private Equity Investor	-
AbCellera Boston, Inc.	Director/Board Member	-
Resolve Therapeutics LLC	Chairman	-
Intermediate Capital Group Plc (Private Equity)	Private Equity Investor	-

Anciens postes connus de Peter Kiener

Sociétés	Poste	Fin
░░░░░░░░ ░░░░	░░░░░ ░░░░░░░░░ ░░░░░░░	░░░░░░░░░░
░░ ░░░░░░░░░░ ░░░░	░░░░░░░░░░░░░░ ░░░░░░	░░░░░░░░░░
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░	░░░░░ ░░░░░░░░░░░░ ░░░░░░░	░░░░░░░░░░
░░░░░ ░░░	░░░░░ ░░░░░░░░░░░░ ░░░░░░░	░░░░░░░░░░
░░░░░░░░░ ░░░░	░░░░░░░	░░░░░░░░░░

Formation de Peter Kiener

University of Oxford	Doctorate Degree
University of Lancaster	Undergraduate Degree